The tRF-5026A and tRF-Glu-TTC-027 can inhibit the occurrence and development of GC through the phosphatase and tensin homolog (PTEN), phosphoinositide 3-kinase (PI3K), AKT, and mitogen-activated protein kinase (MAPK) signaling pathways, respectively (57, 58) (Table 1). The gene discussed is AKT1; the disease is gastric cancer.